Preventing Bacterial Translocation in Patients with Leaky Gut Syndrome: Nutrition and Pharmacological Treatment Options
- PMID: 35328624
- PMCID: PMC8949204
- DOI: 10.3390/ijms23063204
Preventing Bacterial Translocation in Patients with Leaky Gut Syndrome: Nutrition and Pharmacological Treatment Options
Abstract
Leaky gut syndrome is a medical condition characterized by intestinal hyperpermeability. Since the intestinal barrier is one of the essential components maintaining homeostasis along the gastrointestinal tract, loss of its integrity due to changes in bacterial composition, decreased expression levels of tight junction proteins, and increased concentration of pro-inflammatory cytokines may lead to intestinal hyperpermeability followed by the development of gastrointestinal and non-gastrointestinal diseases. Translocation of microorganisms and their toxic metabolites beyond the gastrointestinal tract is one of the fallouts of the leaky gut syndrome. The presence of intestinal bacteria in sterile tissues and distant organs may cause damage due to chronic inflammation and progression of disorders, including inflammatory bowel diseases, liver cirrhosis, and acute pancreatitis. Currently, there are no medical guidelines for the treatment or prevention of bacterial translocation in patients with the leaky gut syndrome; however, several studies suggest that dietary intervention can improve barrier function and restrict bacteria invasion. This review contains current literature data concerning the influence of diet, dietary supplements, probiotics, and drugs on intestinal permeability and bacterial translocation.
Keywords: bacterial translocation; leaky gut syndrome; nutrients; probiotics.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Bacterial Translocation from the Gut to the Distant Organs: An Overview.Ann Nutr Metab. 2017;71 Suppl 1:11-16. doi: 10.1159/000479918. Epub 2017 Sep 28. Ann Nutr Metab. 2017. PMID: 28950279 Review.
-
Leaky Gut: Effect of Dietary Fiber and Fats on Microbiome and Intestinal Barrier.Int J Mol Sci. 2021 Jul 16;22(14):7613. doi: 10.3390/ijms22147613. Int J Mol Sci. 2021. PMID: 34299233 Free PMC article. Review.
-
Leaky Gut and the Ingredients That Help Treat It: A Review.Molecules. 2023 Jan 7;28(2):619. doi: 10.3390/molecules28020619. Molecules. 2023. PMID: 36677677 Free PMC article. Review.
-
Role of Cytochromes P450 in Intestinal Barrier Function: Possible Involvement in the Pathogenesis of Leaky Gut Syndrome.Dig Dis Sci. 2025 Apr;70(4):1293-1304. doi: 10.1007/s10620-025-08873-8. Epub 2025 Feb 19. Dig Dis Sci. 2025. PMID: 39971825 Review.
-
Enteric Pathogens and Their Toxin-Induced Disruption of the Intestinal Barrier through Alteration of Tight Junctions in Chickens.Toxins (Basel). 2017 Feb 10;9(2):60. doi: 10.3390/toxins9020060. Toxins (Basel). 2017. PMID: 28208612 Free PMC article. Review.
Cited by
-
Treating Leaky Syndrome in the Over 65s: Progress and Challenges.Clin Interv Aging. 2023 Aug 31;18:1447-1451. doi: 10.2147/CIA.S409801. eCollection 2023. Clin Interv Aging. 2023. PMID: 37671072 Free PMC article.
-
Potential mechanisms of traditional Chinese medicine in the treatment of liver cirrhosis: a focus on gut microbiota.Front Microbiol. 2024 Aug 21;15:1407991. doi: 10.3389/fmicb.2024.1407991. eCollection 2024. Front Microbiol. 2024. PMID: 39234554 Free PMC article. Review.
-
Protective Effect of Procyanidin-Rich Grape Seed Extract against Gram-Negative Virulence Factors.Antibiotics (Basel). 2023 Nov 10;12(11):1615. doi: 10.3390/antibiotics12111615. Antibiotics (Basel). 2023. PMID: 37998817 Free PMC article.
-
Gut Microbiota in Chronic Kidney Disease: From Composition to Modulation towards Better Outcomes-A Systematic Review.J Clin Med. 2023 Mar 1;12(5):1948. doi: 10.3390/jcm12051948. J Clin Med. 2023. PMID: 36902734 Free PMC article. Review.
-
Potential Immunologic and Integrative Methods to Enhance Vaccine Safety.Vaccines (Basel). 2022 Jul 11;10(7):1108. doi: 10.3390/vaccines10071108. Vaccines (Basel). 2022. PMID: 35891272 Free PMC article.
References
-
- Sperber A.D., Bangdiwala S.I., Drossman D.A., Ghoshal U.C., Simren M., Tack J., Whitehead W.E., Dumitrascu D.L., Fang X., Fukudo S., et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021;160:99–114.e3. doi: 10.1053/j.gastro.2020.04.014. - DOI - PubMed
-
- Kato T., Honda Y., Kurita Y., Iwasaki A., Sato T., Kessoku T., Uchiyama S., Ogawa Y., Ohkubo H., Higurashi T., et al. Lubiprostone improves intestinal permeability in humans, a novel therapy for the leaky gut: A prospective randomized pilot study in healthy volunteers. PLoS ONE. 2017;12:e0175626. doi: 10.1371/journal.pone.0175626. - DOI - PMC - PubMed
-
- Borisova M.A., Achasova K.M., Morozova K.N., Andreyeva E.N., Litvinova E.A., Ogienko A.A., Morozova M.V., Berkaeva M.B., Kiseleva E., Kozhevnikova E.N. Mucin-2 knockout is a model of intercellular junction defects, mitochondrial damage and ATP depletion in the intestinal epithelium. Sci. Rep. 2020;10:21135. doi: 10.1038/s41598-020-78141-4. - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical